We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
-15.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.41B
AUM Growth
-$2.89B
(-35%)
Cap. Flow
-$1.47B
Cap. Flow
% of AUM
-27.24%
Top 10 Holdings %
Top 10 Hldgs %
37.29%
Holding
165
New
19
Increased
15
Reduced
46
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOGC
LogicBio Therapeutics, Inc. Common Stock
LOGC
|
+$78.1M |
| 2 |
THOR
Synthorx, Inc. Common Stock
THOR
|
+$77.1M |
| 3 |
CVS Health
CVS
|
+$59.3M |
| 4 |
CELG
Celgene Corp
CELG
|
+$58.5M |
| 5 |
Guardant Health
GH
|
+$56.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$149M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$98.5M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$81.7M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$81M |
| 5 |
Edwards Lifesciences
EW
|
+$79.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.11% |
| 2 | Financials | 0.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Arvinas
ARVN
$530M
| $34.4M | 0.64% |
2,678,810
+32,945
| +1% | +$523K |
|
|
OBSV
52
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $33M | 0.61% |
2,605,531
| – | – |
|
53
Abbott
ABT
$191B
| $32.4M | 0.6% |
448,400
+54,300
| +14% | +$3.82M |
|
|
AERI
54
DELISTED
Aerie Pharmaceuticals
AERI
| $31.5M | 0.58% |
872,100
-347,730
| -29% | -$16.3M |
|
|
VRAY
55
DELISTED
ViewRay, Inc.
VRAY
| $31.3M | 0.58% |
5,149,019
-587,248
| -10% | -$4.4M |
|
56
Ironwood Pharmaceuticals
IRWD
$604M
| $29.8M | 0.55% |
3,436,332
-61,193
| -2% | -$702K |
|
57
Gilead Sciences
GILD
$166B
| $27.8M | 0.51% |
443,800
+79,200
| +22% | +$5.54M |
|
58
DaVita
DVA
$15.5B
| $27.5M | 0.51% |
534,000
-911,700
| -63% | -$58.4M |
|
|
59
Bristol-Myers Squibb
BMY
$130B
| $26.3M | 0.49% |
505,900
-1,519,900
| -75% | -$81.7M |
|
60
Pfizer
PFE
$144B
| $26.3M | 0.49% |
634,719
-70,091
| -10% | -$2.91M |
|
|
SHPG
61
CALL
DELISTED
Shire pic
SHPG
| $26.1M | 0.48% |
+150,000
| New | +$26.2M |
|
62
Rhythm Pharmaceuticals
RYTM
$7.39B
| $25M | 0.46% |
928,500
-112,853
| -11% | -$3.12M |
|
63
Amgen
AMGN
$212B
| $23.8M | 0.44% |
122,100
-29,500
| -19% | -$5.76M |
|
64
ProQR Therapeutics
PRQR
$246M
| $22.7M | 0.42% |
1,437,731
-600,144
| -29% | -$11M |
|
65
Assembly Biosciences
ASMB
$496M
| $22.5M | 0.42% |
83,010
-19,771
| -19% | -$5.72M |
|
66
Corvus Pharmaceuticals
CRVS
$1.1B
| $21.9M | 0.41% |
5,967,584
| – | – |
|
67
SI-BONE Inc
SIBN
$804M
| $20.6M | 0.38% |
+985,368
| New | +$18.6M |
|
68
Stryker
SYK
$134B
| $20.4M | 0.38% |
130,200
| – | – |
|
|
SPPI
69
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $19.8M | 0.37% |
2,265,500
| – | – |
|
|
SVA
70
DELISTED
Sinovac Biotech, Ltd
SVA
| $19.7M | 0.36% |
2,839,500
| – | – |
|
|
FOMX
71
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $18.7M | 0.34% |
5,195,330
| – | – |
|
72
KALA BIO
KALA
$12M
| $16.9M | 0.31% |
1,381
| – | – |
|
73
DexCom
DXCM
$29.2B
| $16.6M | 0.31% |
+554,800
| New | +$17.6M |
|
|
MYOK
74
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $16.4M | 0.3% |
+335,100
| New | +$18.4M |
|
75
Spyre Therapeutics
SYRE
$8.31B
| $16.2M | 0.3% |
86,621
| – | – |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q4 2018 Portfolio in Review
As of Q4 2018, OrbiMed held 165 positions worth $5.41B, down 35% from $8.3B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
OrbiMed withdrew a net $1.47B in Q4 2018, closing 34 positions and reducing 46 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Financials.
Against the trend, OrbiMed opened a new position in LogicBio Therapeutics, Inc. Common Stock worth $67.3M.
- OrbiMed's largest Q4 2018 buy was LogicBio Therapeutics, Inc. Common Stock: 6,466,783 shares worth $67.3M.
- OrbiMed added most to Celgene Corp in Q4 2018, an estimated $58.5M increase.
- OrbiMed's biggest Q4 2018 reduction was Alexion Pharmaceuticals, cutting an estimated $98.5M.
- OrbiMed fully exited Jazz Pharmaceuticals in Q4 2018, selling an estimated $149M.
- OrbiMed's ten largest holdings make up 37% of its $5.41B portfolio in Q4 2018.
- OrbiMed opened 19 new positions and closed 34 in Q4 2018.
- OrbiMed's portfolio value fell 35% quarter-over-quarter to $5.41B.
Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.